drugset / Trial / NCT03512236

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

NCT03512236

Phase 1 Completed 24 enrolled Adocia
RandomizedCrossoverTriple-blindTreatment

Summary

This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus.

Timeline

Start
2018-04-25
Primary completion
2019-02-14
Completion
2019-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BC Pram Ins Unknown Subcutaneous
Comparator Insulin Protein / enzyme biologic Subcutaneous
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous
Comparator Pramlintide Peptide Subcutaneous